MacroGenics adds two physician-executives to board of directors

MacroGenics, Inc. announced on November 3, 2026 that Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., have been appointed as independent directors to its Board of Directors, effective October 30, 2026.¹

According to the company's 8-K filing, the Board, acting on the recommendation of its Nominating and Governance Committee, voted to expand its membership from ten to eleven seats.¹ Vasconcelles was named a Class II Director and Kuriakose a Class III Director, both effective October 30, 2026.¹ Vasconcelles's term runs until the 2027 annual meeting of stockholders, while Kuriakose's extends to the 2028 annual meeting, in each case subject to earlier departure.¹ The Board determined both new directors meet Nasdaq and Exchange Act independence standards.¹ Both were also added to the Board's Science and Technology Committee.¹

Under the company's compensation program, each new director will receive an option to purchase 44,000 shares of common stock along with a restricted stock unit grant for 7,500 shares under the 2023 Equity Incentive Plan.¹ The option will vest in 36 equal monthly installments and the RSUs in three equal annual installments, contingent on continued service.¹ The filing states neither director was selected under any arrangement with another party, nor has either engaged in a related-party transaction reportable under SEC rules.¹

Kuriakose most recently served as Chief Medical Officer of Terns Pharmaceuticals, where he led development of TERN-701 in chronic myeloid leukemia and TERN-601 in obesity, and contributed to business development work that led to Terns' acquisition by Merck in 2026.¹ Vasconcelles most recently served as Head of Research and Development at Day One Biopharmaceuticals, where he helped expand the company's pipeline beyond OJEMDA (tovorafenib), including through its acquisition of Mersana Therapeutics.¹